menu
    • menu

    Company profile for BioAegis Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a clinical stage private company focused on developing therapies for infectious, inflammatory and degenerative diseases. Our programs capitalize on Evolutionary Wisdom with a natural protein, plasma gelsolin, which has fulfilled this role for vertebrates for millennia. Plasma Gelsolin (“pGSN”) is a master regulator of the immune system. It is a unique anti-inflammatory without immunosuppressive properties.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BioAegis TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    675 US Route 1, North Brunswick, New Jersey 08902
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bioaegistherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/bioaegis-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BioAegis Gets Fast Track for Gelsolin in Decompression Sickness
    BioAegis Gets Fast Track for Gelsolin in Decompression Sickness

    20 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/20/3136592/0/en/BioAegis-Therapeutics-Awarded-Second-FDA-Fast-Track-Designation-for-Recombinant-Human-Gelsolin-to-Treat-Inflammasome-Driven-Decompression-Sickness-DCS.html

    GLOBENEWSWIRE
    20 Aug 2025
    Share Share
    BioAegis Receives FDA Fast Track Designation for Lead Product
    BioAegis Receives FDA Fast Track Designation for Lead Product

    17 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/17/3101007/0/en/BioAegis-Therapeutics-Receives-FDA-Fast-Track-Designation-for-Lead-Product-Recombinant-Human-Gelsolin-for-the-Treatment-of-Acute-Respiratory-Distress-Syndrome-ARDS.html

    GLOBENEWSWIRE
    17 Jun 2025
    Share Share
    BioAegis Therapeutics gets US Navy contract for Phase 2 study of
    BioAegis Therapeutics gets US Navy contract for Phase 2 study of

    10 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/10/3097181/0/en/BioAegis-Therapeutics-Announces-US-Navy-Contract-to-Support-Phase-2-Study-of-Recombinant-Human-Gelsolin-for-Inflammasome-Driven-Decompression-Sickness-DCS.html

    GLOBENEWSWIRE
    10 Jun 2025
    Share Share
    BioAegis Therapeutics Starts Ph 2b Trial in 13 Countries for ARDS
    BioAegis Therapeutics Starts Ph 2b Trial in 13 Countries for ARDS

    06 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/07/3075697/0/en/BioAegis-Therapeutics-Announces-Site-Activation-and-Patient-Recruitment-Underway-in-13-Countries-in-Phase-2b-Clinical-Trial-of-Gelsolin-an-Immune-Regulator-for-the-Treatment-of-Acu.html

    GLOBENEWSWIRE
    06 May 2025
    Share Share
    BioAegis Therapeutics to Highlight Gelsolin's Role at Conferences
    BioAegis Therapeutics to Highlight Gelsolin's Role at Conferences

    18 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/03/18/3044897/0/en/BioAegis-Therapeutics-to-Highlight-Lead-Product-Gelsolin-s-Critical-Role-in-Immune-Function-at-Upcoming-Conferences.html

    GLOBENEWSWIRE
    18 Mar 2025
    Share Share
    BioAegis Enrolls First Patient In ARDS Phase 2 Trial Of Gelsolin
    BioAegis Enrolls First Patient In ARDS Phase 2 Trial Of Gelsolin

    22 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/22/2966612/0/en/BioAegis-Therapeutics-Enrolls-First-Patient-in-Phase-2-Clinical-Trial-of-Gelsolin-an-Immune-Regulator-for-the-Treatment-of-Acute-Respiratory-Distress-Syndrome-ARDS.html

    GLOBENEWSWIRE
    22 Oct 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search